Researchers from Philochem AG recently reported the discovered OncoFAP, a high-affinity small organic ligand of fibroblast activation protein (FAP) that has shown rapid accumulation in tumors and low uptake in healthy tissues in preclinical models.
Angiogenesis plays a crucial role in multiple myeloma and its prognosis, with the success of antiangiogenic therapies being limited. Exosomes mediate cell-to-cell cross talk during the progression of cancer by transporting their molecular cargo, which include long non-coding RNAs (lncRNAs); their role in multiple myeloma was investigated.
Revir Therapeutics Inc. has announced the achievement of a milestone under its ongoing collaboration with Asieris Pharmaceuticals Co. Ltd. to develop treatments for cancers using a novel target.
The development of resistance and relapse during the blast phase of chronic myeloid leukemia poses a challenge in the management of this pathology, with half of the cases accounting for FLT3 pathway activation that, in turn, contributes to tyrosine kinase inhibitor resistance.
B-cell lymphoma 6 (BCL6) is up-regulated in several B-cell malignancies where it acts as a transcription factor activity mediator to induce and maintain lymphomagenesis.
The adverse effects of PD-1 blockers on the CNS observed in cancer patients could occur through their effects on an enzyme that activates microglia. Pharmacological inhibition of the enzyme in mice reduced microglial activation and cognitive deficit without altering the antitumor capacity of the immunotherapy.
Researchers at Rheinisch-Westfaelische Technische Hochschule Aachen University and University of Arizona have synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a DYRK1A and/or DYRK1B and/or DYRK2 and/or DYRK3 and/or CLK1 and/or CLK2 and/or CLK3 and/or CLK4 and/or HASPIN targeting moiety through a linker reported to be useful for the treatment of cancer, viral infection, diabetes, inflammatory disorders, Alzheimer’s, Parkinson’s, Huntington’s and autoimmune diseases, among others.
The overexpression of choline-kinase alpha (CKα) promotes aberrant choline metabolism in epithelial ovarian cancer, thus increasing phosphocholine- and total choline-containing compounds. Previous findings had shown that silencing CKα impacted cell proliferation, migration and invasion, and CKα was hypothesized to be a potential new therapeutic target for ovarian cancer.
Zymeworks Inc. has obtained IND clearance from the FDA for ZW-171, a novel T-cell targeting bispecific antibody for mesothelin (MSLN)-expressing cancers. Clinical development will begin this year, and additional applications will be filed in the second half of the year seeking trial clearances in other territories.
RSS
